ANCOBON PRESCRIBING INFORMATION PDF

Home  /   ANCOBON PRESCRIBING INFORMATION PDF

Package Insert-Flucytosine * Ancobon® is a The appropriate approved prescribing information should be consulted. Images. Group: antifungal. Capsule, mg [EDL] Solution for injection, g in ml [ EDL]. General information. Flucytosine is a fluorinated pyrimidine, non-antibiotic . Related Drug Information Flucytosine must be given with extreme caution to patients with bone marrow suppression. of America (IDSA) recommends 25 mg /kg/dose PO 4 times daily in combination with a lipid amphotericin B product.

Author: Aragore Dasida
Country: Thailand
Language: English (Spanish)
Genre: Science
Published (Last): 18 April 2012
Pages: 158
PDF File Size: 2.53 Mb
ePub File Size: 10.97 Mb
ISBN: 759-7-52107-908-8
Downloads: 7362
Price: Free* [*Free Regsitration Required]
Uploader: Misida

PDR Search

Antimycotic anocbon ATC Code: The risk or severity of adverse effects can be increased when Flucytosine is combined with Ustekinumab. In some cases, a reduction in the dosage of zidovudine may be warranted. The risk or severity of adverse effects can be increased when Busulfan is combined with Flucytosine. The risk or severity of adverse effects can be increased when Temozolomide is combined with Flucytosine.

The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydrocortisone aceponate. Thus, flucytosine is a precursor of 5-FU, but does not behave like an anticancer drug, because the cytidine deaminase is not present in the human cells.

Marketing authorisation number s 9. If hypokalemia occurs or persists, consider reducing the dichlorphenamide dose or discontinuing dichlorphenamide therapy. The risk or severity of adverse effects can be increased when Efalizumab is combined with Flucytosine. Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Flucytosine. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine.

The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen formaldehyde inactivated can be decreased when used in combination with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Ruxolitinib. Cell membrane target Azoles lanosterol 14 alpha-demethylase inhibitors: The following is suggested as a guide for dosage in patients with severe infection associated with renal impairment: Dichlorphenamide increases potassium excretion and can cause hypokalemia and should be used cautiously with other drugs that may cause hypokalemia including antifungals.

  DVORETSKY CHESS PDF

Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Flucytosine. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Flucytosine. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is It is mainly used in combination with Amphotericin B.

The risk or severity of bleeding can be increased when Pentosan Polysulfate is combined with Flucytosine. Infants, Children, and Adolescents. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Flucytosine. Infusion bottles containing 2. The risk or severity of adverse effects can be increased when Pentostatin is combined with Flucytosine.

The risk or severity of adverse effects can be increased when Flucytosine is combined with Ifosfamide. Ocrelizumab The risk or severity of adverse effects can be increased when Flucytosine is combined with Ocrelizumab.

Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed. Views Read Edit View history. Siltuximab The risk or severity of adverse effects can be increased when Flucytosine is combined with Siltuximab. Continue typing to refine.

Related Drug Information Drug Summary. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Flucytosine. The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Flucytosine. Fluorodeoxyuridine interferes with the enzyme thymidylate synthase.

Ancotil 2.5g/250ml Solution for Infusion

The risk or severity of bleeding can be increased when Dipyridamole is combined with Flucytosine. Hydrocortisone succinate The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydrocortisone succinate. Alefacept The risk or severity prescribign adverse effects can be increased when Alefacept is combined with Flucytosine.

The risk or severity of adverse effects can be increased when Flucytosine is combined with Dexamethasone isonicotinate.

  LEXMARK S605 MANUAL PDF

Flucytosine Capsules, USP | Rising Pharmaceuticals

Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Flucytosine. The risk or severity of prescribkng can be increased when Tenecteplase is combined with Flucytosine. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined ihformation Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Flucytosine.

Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ancogon.

The risk or severity of bleeding can be increased when Fondaparinux is combined with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Antilymphocyte immunoglobulin horse.

Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Flucytosine.

Triptolide The risk or severity of adverse effects can be increased when Flucytosine is combined with Triptolide.

Inofrmation of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. Typhoid Vaccine The therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Flucytosine. The outcome of therapy will be affected by variations in the sensitivity of the infection organism, its accessibility and its susceptibility to Ancotil, as well as by differences in the response of individual patients.

Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flucytosine. The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Flucytosine. In isolated cases, bone marrow ancobo may be irreversible and could lead to death in patients with pre-existing immuno-suppression, Local irritation or phlebitis does not appear to be a problem with Ancotil for Infusion.